CoChat

Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Open access
Wang, Yafang, Yao, Mingyue, Li, Cheng, Yang, Kexin, Qin, Xiaolong, Xu, Lansong, Shi, Shangxuan, Yu, Chengcheng, Meng, Xiangjun, Xie, Chengying · 2023 · Experimental Hematology & Oncology

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Background: KRAS G12C inhibitors (KRAS G12C i) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRAS G12C-mutant cancers. However, the emergence of therapy-related drug resistance limits their long-term potential. This study aimed to identify the critical mediators and develop overcoming strategies. Methods: By using RNA sequencing, RT-qPCR and immunoblotting, we identified and validated the upregulation of c-Myc activity and the amplification of the long noncoding RNA ST8SIA6-AS1 in KRAS G12C i-resistant cells. The regulatory axis ST8SIA6-AS1/Polo-like kinase 1 (PLK1)/c-Myc was investigated by bioinformatics, RNA fluorescence in situ hybridization, RNA immunoprecipitation, RNA pull-down and chromatin immunoprecipitation. Gain/loss-of-function assays, cell viability assay, xenograft models, and IHC staining were conducted to evaluate the anti-cancer effects of co-inhibition of ST8SIA6-AS1/PLK1 pathway and KRAS both in vitro and in vivo. Results: KRAS G12C i sustainably decreased c-Myc levels in responsive cell lines but not in cell lines with intrinsic or acquired resistance to KRAS G12C i. PLK1 activation contributed to this ERK-independent c-Myc stability, which in turn directly induced PLK1 transcription, forming a positive feedback loop and conferring resistance to KRAS G12C i. ST8SIA6-AS1 was found significantly upregulated in resistant cells and facilitated the proliferation of KRAS G12C-mutant cancers. ST8SIA6-AS1 bound to Aurora kinase A (Aurora A)/PLK1 and promoted Aurora A-mediated PLK1 phosphorylation. Concurrent targeting of KRAS and ST8SIA6-AS1/PLK1 signaling suppressed both ERK-dependent and -independent c-Myc expression, synergistically led to cell death and tumor regression and overcame KRAS G12C i resistance. Conclusions: Our study deciphers that the axis of ST8SIA6-AS1/PLK1/c-Myc confers both intrinsic and acquired resistance to KRAS G12C i and represents a promising therapeutic target for combination strategies with KRAS G12C i in the treatment of KRAS G12C-mutant cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40164-023-00466-3

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 ERK-independent c-Myc signal predicts for the response to KRASG12Ci and contributes to KRASG12Ci resistance. A The cytotoxicity of AMG510 and MRTX849 in six human KRASG12C-mutant cell lines were tested by sulforhodamine B (SRB) assay (n = 3). B IC50s of AMG510 and MRTX849 matching parental and resistant cells. C The hierarchical clustering and heatmap showed the expression profile of the differentially expressed genes (DEGs) in signal transduction pathway from MIA PaCa-2 parental and resistant cells. D GSEA showed that gene sets related to MYC targets (left) and CYCLIN D1 signaling (right) were enriched in the KRASG12Ci-resistant cells. E The mRNA levels of the MYC target genes were tested by RT-qPCR. F Expression of c-Myc in LUAD (n = 511) and COAD (n = 402) patients with wild-type or mutant KRAS from TCGA database. The indicated P-values were analyzed by Wilcoxon test. G Western blot analysis of KRASG12C-mutant cell lines after dose-dependent (0, 1, 10, 100, 1000 nM) treatment of AMG510 or MRTX849. H Association between c-Myc alteration upon KRASG12Ci treatment for 24 h versus KRASG12Ci sensitivity. Shown were the quantitative results of immunoblotting data in G. I Western blot analysis of protein lysates from c-Myc-overexpressed MIA PaCa-2 and NCI-H358 cells cultured with or without 100 nM AMG510 for 24 h. J Relative cell viability of c-Myc- or vector- expressing MIA PaCa-2 and NCI-H358 cells treated with increasing concentrations of KRASG12Ci for 72 h. K Colony formation of cells transfected with vector or pCDH-c-Myc plasmid and treated with or without 5 nM AMG510. L Western blot analysis of protein lysates from MIA PaCa-2-R and SW1573 cells cultured with KRASG12Ci in combination with MYCi975 for 24 h. M Relative cell viability of MIA PaCa-2-R and SW1573 cells treated with 1 µM KRASG12Ci in combination with 6 µM MYCi975 for 5 days was analyzed by SRB assay (n = 3). N Colony formation of cells cultured with 1 µM KRASG12Ci in combination with 2 µM MYCi975. Data represent the average and standard deviation (SD). Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Figs. S1, S2
Fig. 1 ERK-independent c-Myc signal predicts for the response to KRASG12Ci and contributes to KRASG12Ci resistance. A The cytotoxicity of AMG510 and MRTX849 in six human KRASG12C-mutant cell lines were tested by sulforhodamine B (SRB) assay (n = 3). B IC50s of AMG510 and MRTX849 matching parental and resistant cells. C The hierarchical clustering and heatmap showed the expression profile of the differentially expressed genes (DEGs) in signal transduction pathway from MIA PaCa-2 parental and resistant cells. D GSEA showed that gene sets related to MYC targets (left) and CYCLIN D1 signaling (right) were enriched in the KRASG12Ci-resistant cells. E The mRNA levels of the MYC target genes were tested by RT-qPCR. F Expression of c-Myc in LUAD (n = 511) and COAD (n = 402) patients with wild-type or mutant KRAS from TCGA database. The indicated P-values were analyzed by Wilcoxon test. G Western blot analysis of KRASG12C-mutant cell lines after dose-dependent (0, 1, 10, 100, 1000 nM) treatment of AMG510 or MRTX849. H Association between c-Myc alteration upon KRASG12Ci treatment for 24 h versus KRASG12Ci sensitivity. Shown were the quantitative results of immunoblotting data in G. I Western blot analysis of protein lysates from c-Myc-overexpressed MIA PaCa-2 and NCI-H358 cells cultured with or without 100 nM AMG510 for 24 h. J Relative cell viability of c-Myc- or vector- expressing MIA PaCa-2 and NCI-H358 cells treated with increasing concentrations of KRASG12Ci for 72 h. K Colony formation of cells transfected with vector or pCDH-c-Myc plasmid and treated with or without 5 nM AMG510. L Western blot analysis of protein lysates from MIA PaCa-2-R and SW1573 cells cultured with KRASG12Ci in combination with MYCi975 for 24 h. M Relative cell viability of MIA PaCa-2-R and SW1573 cells treated with 1 µM KRASG12Ci in combination with 6 µM MYCi975 for 5 days was analyzed by SRB assay (n = 3). N Colony formation of cells cultured with 1 µM KRASG12Ci in combination with 2 µM MYCi975. Data represent the average and standard deviation (SD). Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Figs. S1, S2CC BY · PubMed Central
Fig. 2 The reciprocal activation of PLK1/c-Myc pathway associates with KRASG12Ci resistance. A GSEA displayed the gene set related to Hallmark G2/M checkpoint. B The hierarchical clustering and heatmap of the gene expressions related to G2/M checkpoint. C The mRNA levels of PLK4 and PLK1 in MIA PaCa-2 or NCI-H358 parental and resistant cells were tested by RT-qPCR. D PLK1 expression is positively correlated with MYC expression in lung and pancreatic cancer patients from GEPIA2 database. E Western blot analysis of MIA PaCa-2 or NCI-H358 parental and resistant cells after time-dependent treatments of 100 nM AMG510. F Western blot analysis of cells treated with siPLK1s or 20 nM PLK1i for 48 h. G MIA PaCa-2-R cells transfected with siNC or siPLK1 were treated with 20 µg/mL CHX for different times and harvested for western blot. The protein abundance of c-Myc was quantified using Image J. H C-Myc protein levels were restored by MG132 (10 µM) treatment (6 h) in PLK1-knockdown or Volasertib-treated MIA PaCa-2-R cells. I Cell viability of untreated or KRASG12Ci-treated (1µM, 72 h) MIA PaCa-2-R, NCI-H358-R and SW1573 cells with PLK1 knockdown (n = 3). J Cell apoptosis of PLK1-knockdown SW1573 cells exposed to 100 nM AMG510 for another 24 h. K PLK1-overexpressed MIA PaCa-2 and NCI-H358 cells were cultured with and without 100 nM AMG510 for 24 h and subjected to western blot analysis. L AMG510 or MRTX849 dose-response curve for PLK1- or vector- expressing cells (n = 3). M Clonogenic growth of MIA PaCa-2 and NCI-H358 cells transfected with mock or pcDNA3-PLK1 plasmid and treated with or without 5 nM AMG510. N mRNA and protein levels of MYC and PLK1 were assessed under basal conditions or Dox induction (0.5 µM/mL) for 12 h in 293T cells expressing FUW-tetO-hMYC. O Western blot analysis of MIA PaCa-2 cells transfected with vector or pCDH-c-Myc plasmid. mRNA (P) and protein (Q) levels of MYC and PLK1 were assessed in control or c-Myc-knockdown cells. R Schematic diagram showed that a c-Myc E-box binding site (CACGTG) existed about 80 bp upstream of the PLK1 transcription start site (TSS, GeneBank accession number: NC_000016.10) (upper panel). ChIP immunoprecipitation of c-Myc recruitment to the proximal (pro1) and distal (pro2) regions of PLK1 promoter was analyzed and normalized to the input in KRAS-mutant cells (lower panel). Data represent mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S3
Fig. 2 The reciprocal activation of PLK1/c-Myc pathway associates with KRASG12Ci resistance. A GSEA displayed the gene set related to Hallmark G2/M checkpoint. B The hierarchical clustering and heatmap of the gene expressions related to G2/M checkpoint. C The mRNA levels of PLK4 and PLK1 in MIA PaCa-2 or NCI-H358 parental and resistant cells were tested by RT-qPCR. D PLK1 expression is positively correlated with MYC expression in lung and pancreatic cancer patients from GEPIA2 database. E Western blot analysis of MIA PaCa-2 or NCI-H358 parental and resistant cells after time-dependent treatments of 100 nM AMG510. F Western blot analysis of cells treated with siPLK1s or 20 nM PLK1i for 48 h. G MIA PaCa-2-R cells transfected with siNC or siPLK1 were treated with 20 µg/mL CHX for different times and harvested for western blot. The protein abundance of c-Myc was quantified using Image J. H C-Myc protein levels were restored by MG132 (10 µM) treatment (6 h) in PLK1-knockdown or Volasertib-treated MIA PaCa-2-R cells. I Cell viability of untreated or KRASG12Ci-treated (1µM, 72 h) MIA PaCa-2-R, NCI-H358-R and SW1573 cells with PLK1 knockdown (n = 3). J Cell apoptosis of PLK1-knockdown SW1573 cells exposed to 100 nM AMG510 for another 24 h. K PLK1-overexpressed MIA PaCa-2 and NCI-H358 cells were cultured with and without 100 nM AMG510 for 24 h and subjected to western blot analysis. L AMG510 or MRTX849 dose-response curve for PLK1- or vector- expressing cells (n = 3). M Clonogenic growth of MIA PaCa-2 and NCI-H358 cells transfected with mock or pcDNA3-PLK1 plasmid and treated with or without 5 nM AMG510. N mRNA and protein levels of MYC and PLK1 were assessed under basal conditions or Dox induction (0.5 µM/mL) for 12 h in 293T cells expressing FUW-tetO-hMYC. O Western blot analysis of MIA PaCa-2 cells transfected with vector or pCDH-c-Myc plasmid. mRNA (P) and protein (Q) levels of MYC and PLK1 were assessed in control or c-Myc-knockdown cells. R Schematic diagram showed that a c-Myc E-box binding site (CACGTG) existed about 80 bp upstream of the PLK1 transcription start site (TSS, GeneBank accession number: NC_000016.10) (upper panel). ChIP immunoprecipitation of c-Myc recruitment to the proximal (pro1) and distal (pro2) regions of PLK1 promoter was analyzed and normalized to the input in KRAS-mutant cells (lower panel). Data represent mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S3CC BY · PubMed Central
Fig. 3 PLK1i synergizes with KRASG12Ci via ERK-dependent and -independent downregulation of c-Myc. A Representative Volasertib and BI 2536 dose-response curves and IC50 values of eight cell lines. B Volasertib inhibited the viability of Ba/F3 cells expressing KRASG12C, or KRASG12C second-site mutants. C Relative cell viability of MIA PaCa-2-R, NCI-H358-R and SW1573 cells treated with Volasertib (5 nM), KRASG12Ci (1 µM), or their combination for 72 h. D CI values of PLK1i in combination with KRASG12Ci were tested by cell viability assay and calculated by CalcuSyn software. E Clonogenic growth of cells treated with Volasertib (2 nM) or BI 2536 (1 nM) in combination with KRASG12Ci. Quantified results were shown. Cell cycle (F) and apoptosis analysis (G) of cells treated with PLK1i in combination with KRASG12Ci for 24 h. H Effects of Volasertib (20 nM), AMG510 (100 nM), or their combination (24 h) on histone H3 (Ser10) phosphorylation were shown by immunofluorescence in MIA PaCa-2-R cells. Scale bar, 5 μm. I Immunoblotting of cells treated with PLK1i in combination with AMG510 for 24 h. Data represent mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S4
Fig. 3 PLK1i synergizes with KRASG12Ci via ERK-dependent and -independent downregulation of c-Myc. A Representative Volasertib and BI 2536 dose-response curves and IC50 values of eight cell lines. B Volasertib inhibited the viability of Ba/F3 cells expressing KRASG12C, or KRASG12C second-site mutants. C Relative cell viability of MIA PaCa-2-R, NCI-H358-R and SW1573 cells treated with Volasertib (5 nM), KRASG12Ci (1 µM), or their combination for 72 h. D CI values of PLK1i in combination with KRASG12Ci were tested by cell viability assay and calculated by CalcuSyn software. E Clonogenic growth of cells treated with Volasertib (2 nM) or BI 2536 (1 nM) in combination with KRASG12Ci. Quantified results were shown. Cell cycle (F) and apoptosis analysis (G) of cells treated with PLK1i in combination with KRASG12Ci for 24 h. H Effects of Volasertib (20 nM), AMG510 (100 nM), or their combination (24 h) on histone H3 (Ser10) phosphorylation were shown by immunofluorescence in MIA PaCa-2-R cells. Scale bar, 5 μm. I Immunoblotting of cells treated with PLK1i in combination with AMG510 for 24 h. Data represent mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S4CC BY · PubMed Central
Fig. 4 Co-inhibition of PLK1 and KRASG12C synergistically suppresses tumor growth and overcomes resistance in vivo. Relative tumor volumes (RTV) of KRASG12C-mutant MIA PaCa-2 (A), MIA PaCa-2-R (B) and SW1573 (C) cell xenografts treated with vehicle, MRTX849 (10 or 30 mg/kg/day), Volasertib (20 mg/kg/week), alone or in combination; statistical significance was evaluated by one-way ANOVA with Tukey’s multiple comparison test. *P < 0.05, **P < 0.01, and ***P < 0.001. Data are the mean ± SEM (5 mice/group). Tumors in each model were weighted at the end of the treatments. D–F Changes in tumor volumes of individual mice in MIA PaCa‑2 (D), MIA PaCa‑2-R (E) and SW1573 (F) xenografts at the end of treatment were calculated. G–I Mouse body weights in each model were measured every 3 days during the experiments. J Western blot analyses of the tumor tissues from the above xenografts. K IHC analyses of MIA PaCa-2 and SW1573 tumor tissues after the treatment. Scale bar, 50 μm. Cells positive for c-Myc and cleaved caspase-3 were quantified (n = 3). Data are shown as mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, and ***P < 0.001
Fig. 4 Co-inhibition of PLK1 and KRASG12C synergistically suppresses tumor growth and overcomes resistance in vivo. Relative tumor volumes (RTV) of KRASG12C-mutant MIA PaCa-2 (A), MIA PaCa-2-R (B) and SW1573 (C) cell xenografts treated with vehicle, MRTX849 (10 or 30 mg/kg/day), Volasertib (20 mg/kg/week), alone or in combination; statistical significance was evaluated by one-way ANOVA with Tukey’s multiple comparison test. *P < 0.05, **P < 0.01, and ***P < 0.001. Data are the mean ± SEM (5 mice/group). Tumors in each model were weighted at the end of the treatments. D–F Changes in tumor volumes of individual mice in MIA PaCa‑2 (D), MIA PaCa‑2-R (E) and SW1573 (F) xenografts at the end of treatment were calculated. G–I Mouse body weights in each model were measured every 3 days during the experiments. J Western blot analyses of the tumor tissues from the above xenografts. K IHC analyses of MIA PaCa-2 and SW1573 tumor tissues after the treatment. Scale bar, 50 μm. Cells positive for c-Myc and cleaved caspase-3 were quantified (n = 3). Data are shown as mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, and ***P < 0.001CC BY · PubMed Central
Fig. 5 ST8SIA6-AS1 promotes malignant proliferation of KRASG12C-mutant cancers through Aurora A/PLK1/c-Myc activation. A A table displayed the top 16 most increased lncRNAs in MIA PaCa-2-R cells compared to parental cells. B The volcano plot of the DEGs showing the significantly up-regulated ST8SIA6-AS1. C Association of ST8SIA6-AS1 expression with overall survival (OS) in all lung cancer patients (n = 1880) or colon cancer (n = 1302) patients from TCGA database. D RT-qPCR of ST8SIA6-AS1 expression in six KRASG12C-mutant cell lines. E The relative Aurora A phosphorylation levels in MIA PaCa-2 or NCI-H358 parental and resistant cells were tested by western blotting and quantified. F RNA pull-down by full-length biotin-labeled ST8SIA6-AS1 was then subjected to immunoblotting with PLK1 and Aurora A. G RT-qPCR of ST8SIA6-AS1 retrieved by RNA immunoprecipitation (RIP) with PLK1 or Aurora A antibodies in MIA PaCa-2-R cells. H The co-localization of ST8SIA6-AS1 and PLK1 in MIA PaCa-2-R cells was detected by confocal microscopy. Scale bar, 10 μm. I RT-qPCR showing the nuclear and cytoplasmic fraction of ST8SIA6-AS1 in MIA PaCa-2-R cells, with GAPDH and MALAT1 as cytoplasmic and nuclear control, respectively. J Western blot analysis of phosphorylated PLK1 and Aurora A levels were determined in cells transfected with plasmid pcDNA3.1-ST8SIA6-AS1. K Co-IP with Aurora A antibody in ST8SIA6-AS1-overexpressed cells. L Western blotting of c-Myc in vector- or ST8SIA6-AS1- expressing MIA PaCa-2 cells treated with CHX. The quantification of c-Myc degradation rate by gray scale analysis was shown. M Western blot analysis of phosphorylated PLK1 and Aurora A levels in ST8SIA6-AS1-depleted cells. N The proliferation of ST8SIA6-AS1-overexpressed cells was determined by SRB assay. O Colony formation assay of ST8SIA6-AS1 knockdown cells. P Relative cell viability was tested in ST8SIA6-AS1-overexpressed NCI-H358 and MIA PaCa-2 cells under the treatment of 5 nM Volasertib or 6 µM MYCi975 for 72 h. Data represent the average and SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S5
Fig. 5 ST8SIA6-AS1 promotes malignant proliferation of KRASG12C-mutant cancers through Aurora A/PLK1/c-Myc activation. A A table displayed the top 16 most increased lncRNAs in MIA PaCa-2-R cells compared to parental cells. B The volcano plot of the DEGs showing the significantly up-regulated ST8SIA6-AS1. C Association of ST8SIA6-AS1 expression with overall survival (OS) in all lung cancer patients (n = 1880) or colon cancer (n = 1302) patients from TCGA database. D RT-qPCR of ST8SIA6-AS1 expression in six KRASG12C-mutant cell lines. E The relative Aurora A phosphorylation levels in MIA PaCa-2 or NCI-H358 parental and resistant cells were tested by western blotting and quantified. F RNA pull-down by full-length biotin-labeled ST8SIA6-AS1 was then subjected to immunoblotting with PLK1 and Aurora A. G RT-qPCR of ST8SIA6-AS1 retrieved by RNA immunoprecipitation (RIP) with PLK1 or Aurora A antibodies in MIA PaCa-2-R cells. H The co-localization of ST8SIA6-AS1 and PLK1 in MIA PaCa-2-R cells was detected by confocal microscopy. Scale bar, 10 μm. I RT-qPCR showing the nuclear and cytoplasmic fraction of ST8SIA6-AS1 in MIA PaCa-2-R cells, with GAPDH and MALAT1 as cytoplasmic and nuclear control, respectively. J Western blot analysis of phosphorylated PLK1 and Aurora A levels were determined in cells transfected with plasmid pcDNA3.1-ST8SIA6-AS1. K Co-IP with Aurora A antibody in ST8SIA6-AS1-overexpressed cells. L Western blotting of c-Myc in vector- or ST8SIA6-AS1- expressing MIA PaCa-2 cells treated with CHX. The quantification of c-Myc degradation rate by gray scale analysis was shown. M Western blot analysis of phosphorylated PLK1 and Aurora A levels in ST8SIA6-AS1-depleted cells. N The proliferation of ST8SIA6-AS1-overexpressed cells was determined by SRB assay. O Colony formation assay of ST8SIA6-AS1 knockdown cells. P Relative cell viability was tested in ST8SIA6-AS1-overexpressed NCI-H358 and MIA PaCa-2 cells under the treatment of 5 nM Volasertib or 6 µM MYCi975 for 72 h. Data represent the average and SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S5CC BY · PubMed Central
Fig. 6 Targeting ST8SIA6-AS1 reverses cell resistance to KRASG12Ci in vitro. A Relative cell viability of ST8SIA6-AS1-overexpressed cells under increasing concentrations of KRASG12Ci for 72 h. B Cell colony formation of ST8SIA6-AS1-overexpressed cells treated with or without AMG510. C Western blot analysis of cells with ST8SIA6-AS1 forced expression treated by 100 nM AMG510 for 24 h. ST8SIA6-AS1-knockdown KRASG12Ci resistant cells were treated with 1 µM KRASG12Ci to determine the effect on viability by the SRB assay (72 h) (D) and colony formation assay (E). F Cell apoptosis analysis of ST8SIA6-AS1-knockdown SW1573 cells treated with or without 100 nM KRASG12Ci for 24 h. G The effect of ST8SIA6-AS1 depletion followed by 100 nM AMG510 treatment for 24 h on generating micronuclei and multi-nuclei. MIA PaCa-2-R cells were immunostained with DAPI. The percentages of abnormal mitotic cells were calculated. Scale bar 10 μm. H Immunoblotting of ST8SIA6-AS1 knockdown cells treated with 100 nM KRASG12Ci for 24 h. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S6
Fig. 6 Targeting ST8SIA6-AS1 reverses cell resistance to KRASG12Ci in vitro. A Relative cell viability of ST8SIA6-AS1-overexpressed cells under increasing concentrations of KRASG12Ci for 72 h. B Cell colony formation of ST8SIA6-AS1-overexpressed cells treated with or without AMG510. C Western blot analysis of cells with ST8SIA6-AS1 forced expression treated by 100 nM AMG510 for 24 h. ST8SIA6-AS1-knockdown KRASG12Ci resistant cells were treated with 1 µM KRASG12Ci to determine the effect on viability by the SRB assay (72 h) (D) and colony formation assay (E). F Cell apoptosis analysis of ST8SIA6-AS1-knockdown SW1573 cells treated with or without 100 nM KRASG12Ci for 24 h. G The effect of ST8SIA6-AS1 depletion followed by 100 nM AMG510 treatment for 24 h on generating micronuclei and multi-nuclei. MIA PaCa-2-R cells were immunostained with DAPI. The percentages of abnormal mitotic cells were calculated. Scale bar 10 μm. H Immunoblotting of ST8SIA6-AS1 knockdown cells treated with 100 nM KRASG12Ci for 24 h. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. See also Additional file 2: Fig. S6CC BY · PubMed Central
Fig. 7 Suppression of ST8SIA6-AS1 restores the sensitivity of KRASG12Ci in vivo. A MIA PaCa-2-R cells were inoculated to form xenografts in nude mice (n = 5 mice/group). The administration dose and time of the drugs were recorded. B RTV of MIA PaCa-2-R xenografts treated with vehicle, MRTX849 and ST8SIA6-AS1 siRNA, alone or in combination. Tumor weights were measured after surgical resection. Data are the mean ± SEM (5 mice/group). *P < 0.05, **P < 0.01, and ***P < 0.001 by one-way ANOVA with Tukey’s multiple comparison test. C Changes in tumor volumes of individual mice in MIA PaCa‑2-R xenografts at the end of treatment. D Mouse body weights in MIA PaCa-2-R xenograft model were measured every 3 days during the experiments. Data are the mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. E Western blot analysis of tumor tissues at the end of the treatment. See also Additional file 2: Fig. S6. F Schematic model depicting the mechanism by which concurrent targeting of ST8SIA6-AS1/PLK1/c-Myc axis with KRAS elicits significant KRASG12Ci-resistant cell death
Fig. 7 Suppression of ST8SIA6-AS1 restores the sensitivity of KRASG12Ci in vivo. A MIA PaCa-2-R cells were inoculated to form xenografts in nude mice (n = 5 mice/group). The administration dose and time of the drugs were recorded. B RTV of MIA PaCa-2-R xenografts treated with vehicle, MRTX849 and ST8SIA6-AS1 siRNA, alone or in combination. Tumor weights were measured after surgical resection. Data are the mean ± SEM (5 mice/group). *P < 0.05, **P < 0.01, and ***P < 0.001 by one-way ANOVA with Tukey’s multiple comparison test. C Changes in tumor volumes of individual mice in MIA PaCa‑2-R xenografts at the end of treatment. D Mouse body weights in MIA PaCa-2-R xenograft model were measured every 3 days during the experiments. Data are the mean ± SD. Statistical significance was assessed using two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. E Western blot analysis of tumor tissues at the end of the treatment. See also Additional file 2: Fig. S6. F Schematic model depicting the mechanism by which concurrent targeting of ST8SIA6-AS1/PLK1/c-Myc axis with KRAS elicits significant KRASG12Ci-resistant cell deathCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 27

Metadata

Authors
Wang, Y., Yao, M., Li, C., Yang, K., Qin, X., Xu, L., Shi, S., Yu, C., Meng, X., & Xie, C.
Affiliations
  • University of Science and Technology of China (CN)
  • ShanghaiTech University (CN)
  • Chinese Academy of Sciences (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
Xie, Chengying
Venue
Experimental Hematology & Oncology
Published
2023-12-16
Volume
12
Issue
1
Pages
105-105
ISSN
2162-3619 (ISSN-L)
OpenAlex
W4389832411
Cited by
26
References
69
Citations by year
2026: 8 · 2025: 11 · 2024: 7
FWCI
3.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental Hematology and Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science foundation of Shanghai, China (19ZR1467700)
  • Lingang Laboratory, China (LG202101-01-06)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
KRAS G12C inhibitors, drug resistance, PLK1, c-Myc, long non-coding RNA, AURKA, sotorasib, adagrasib, PLK1 phosphorylation, combination therapy, tumor regression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling. https://app.cochat.ai/papers/10.1186/s40164-023-00466-3
The paper
Wang, Y., Yao, M., Li, C., Yang, K., Qin, X., Xu, L., Shi, S., Yu, C., Meng, X., & Xie, C. (2023). Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-023-00466-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.